2007 Update on Allogeneic Islet Transplantation from the Collaborative Islet Transplant Registry (CITR)
07/2009
Journal Article
Authors:
CITR), T.Collaborat;
Barton, F.B.;
Wease, S.;
Stablein, D.;
Damodharan, Y.;
Heitman, A.;
Wagner, C.;
Danoff, R.
Secondary:
Cell Transplant
Volume:
18
Pagination:
753-767
URL:
http://www.ncbi.nlm.nih.gov/pubmed?term=19796497
Keywords:
diabetes mellitus; Europe; Female; Glycosylated/metabolism; Hemoglobin A; Humans; Hypoglycemia/metabolism; Hypoglycemia/physiopathology; Immunosuppression/adverse effects; Insulin/metabolism; Islets of Langerhans Transplantation/adverse; Type 1/therapy*
Abstract:
{As of October 1, 2007, 25 North American medical institutions and one European islet transplant center reported detailed information to the Registry on 315 allograft recipients, of which 285 were islet alone (IA) and 30 were islet after kidney (IAK). Of the 114 IA recipients expected at 4 years after their last infusion, 12% were insulin independent, 16% were insulin dependent with detectable C-peptide, 40% had no detectable C-peptide, and 32% had missing C-peptide data or were lost to follow-up. Of the IA recipients, 72% achieved insulin independence at least once over 3 years and multiple infusions. Factors associated with achievement of insulin independence included islet size >1.0 expressed as IEQs per islet number [hazard ratio (HR) = 1.5
